SONCINI, DEBORA
 Distribuzione geografica
Continente #
EU - Europa 5.669
AS - Asia 638
NA - Nord America 298
SA - Sud America 50
AF - Africa 12
Totale 6.667
Nazione #
IT - Italia 5.544
US - Stati Uniti d'America 277
SG - Singapore 270
CN - Cina 159
VN - Vietnam 137
FR - Francia 42
BR - Brasile 30
HK - Hong Kong 28
DE - Germania 22
GB - Regno Unito 13
FI - Finlandia 12
MX - Messico 10
AR - Argentina 9
CA - Canada 8
IQ - Iraq 8
BD - Bangladesh 7
IN - India 7
JP - Giappone 7
CH - Svizzera 6
SE - Svezia 6
UA - Ucraina 6
NL - Olanda 5
IE - Irlanda 4
PY - Paraguay 4
AT - Austria 3
EC - Ecuador 3
ID - Indonesia 3
TR - Turchia 3
ZA - Sudafrica 3
DZ - Algeria 2
EG - Egitto 2
MA - Marocco 2
PA - Panama 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BE - Belgio 1
CO - Colombia 1
ES - Italia 1
GA - Gabon 1
HN - Honduras 1
HU - Ungheria 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MG - Madagascar 1
MT - Malta 1
PH - Filippine 1
PK - Pakistan 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 6.667
Città #
Genova 2.844
Genoa 1.811
Rapallo 497
Vado Ligure 329
Singapore 133
San Jose 87
Ashburn 50
Ho Chi Minh City 50
Lauterbourg 39
Beijing 33
Hanoi 30
Hong Kong 27
Frankfurt am Main 18
Council Bluffs 17
New York 13
Da Nang 9
Helsinki 9
Schiavon 9
Los Angeles 8
Rome 8
Bordighera 7
Santa Clara 7
Mexico City 6
Milan 6
São Paulo 6
Tokyo 6
Zurich 6
Montreal 5
Orem 5
Baghdad 4
Buffalo 4
Can Tho 4
Chicago 4
City of London 4
Kyiv 4
Turin 4
Amsterdam 3
Buenos Aires 3
Cardiff 3
Djursholm 3
Dublin 3
Haiphong 3
Hải Dương 3
Lappeenranta 3
Mumbai 3
Phủ Lý 3
Stockholm 3
Tianjin 3
Algiers 2
Asunción 2
Biên Hòa 2
Brooklyn 2
Cuenca 2
Houston 2
Manchester 2
Nha Trang 2
Nuremberg 2
Panama City 2
Paris 2
Parma 2
Poplar 2
Ribeirão Preto 2
Savigliano 2
Suzhou 2
Abu Dhabi 1
Agadir 1
Alcobaça 1
Alfenas 1
Alpine 1
Amman 1
Ankara 1
Antakya 1
Antananarivo 1
Antwerp 1
Araçuaí 1
Armazém 1
Baku 1
Barranquilla 1
Basra 1
Bekasi 1
Belo Horizonte 1
Boa Vista 1
Bologna 1
Budapest 1
Bình Dương 1
Bắc Ninh 1
Cairo 1
Campina Grande 1
Caracas 1
Carney 1
Caroebe Municipality 1
Caroní 1
Casablanca 1
Changsha 1
Chapada Gaúcha 1
Chennai 1
Ciudad del Este 1
Contendas do Sincorá 1
Cuautitlán Izcalli 1
Curuzú Cuatiá 1
Totale 6.207
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 257
1222 POSTER Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 252
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 245
1221 POSTER Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 243
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 240
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 216
Ras-induced resistance to lapatinib is overcome by MEK inhibition 199
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 198
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 198
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 186
CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. 185
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 185
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments. Concordance with experimental results. 178
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 178
Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 174
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 173
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 171
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 166
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. 165
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 163
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 155
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 154
Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors 147
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 146
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 146
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. 143
Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 143
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 136
Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. 135
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 135
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 130
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 123
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 121
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 111
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 106
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 104
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma 98
Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies 89
Sirtuin 6 Regulates the Activation of the ATP/Purinergic Axis in Endothelial Cells 87
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis 87
Targeting the immune microenvironment in Waldenström Macroglobulinemia via halting the CD40/CD40-ligand axis 72
EXTRACELLULAR NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) ARRESTS ENDOTHELIAL CELL PROLIFERATION 65
Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies 57
The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS 45
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 41
Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1 37
Totale 6.785
Categoria #
all - tutte 20.325
article - articoli 19.880
book - libri 0
conference - conferenze 445
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.650


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021104 0 0 0 0 0 0 0 0 0 44 41 19
2021/2022466 15 21 35 74 18 36 22 97 20 39 28 61
2022/2023603 55 59 10 92 101 72 8 43 83 9 63 8
2023/2024358 10 28 15 52 34 78 14 45 13 3 15 51
2024/20251.102 37 61 16 81 102 104 91 219 41 73 133 144
2025/20261.798 265 81 141 198 282 143 251 106 161 170 0 0
Totale 6.785